Cargando…

Benefit–Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER

BACKGROUND: Thromboprophylaxis extended after hospital discharge in medically ill patients currently is not recommended by practice guidelines because of uncertainty about the benefit for preventing major or fatal thromboembolic events, and the risk of bleeding. METHODS AND RESULTS: We assessed the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raskob, Gary E., Spyropoulos, Alex C., Spiro, Theodore E., Lu, Wentao, Yuan, Zhong, Levitan, Bennett, Suh, Eunyoung, Barnathan, Elliot S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751917/ https://www.ncbi.nlm.nih.gov/pubmed/34755519 http://dx.doi.org/10.1161/JAHA.121.021579

Ejemplares similares

Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study
por: Spyropoulos, Alex C., et al.
Publicado: (2019)

Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
por: Raskob, Gary E., et al.
Publicado: (2022)

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
por: Cohen, Alexander Thomas, et al.
Publicado: (2011)

Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
por: Ageno, Walter, et al.
Publicado: (2021)

Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis
por: Spyropoulos, Alex C., et al.
Publicado: (2020)

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021)

Hospital-based use of thromboprophylaxis in patients with COVID-19
por: Spyropoulos, Alex C, et al.
Publicado: (2020)

Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
por: Spyropoulos, Alex C., et al.
Publicado: (2020)

New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients
por: MacDougall, Kira, et al.
Publicado: (2020)

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
por: Capell, Warren H., et al.
Publicado: (2021)

Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients
por: Raskob, Gary E., et al.
Publicado: (2021)

Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study
por: Carvalho de Oliveira, Caroline Cândida, et al.
Publicado: (2023)

Thromboprophylaxis in critical care
por: Helms, Julie, et al.
Publicado: (2022)

Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis
por: Coleman, Craig I., et al.
Publicado: (2020)

Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease
por: Volkl, Albert A., et al.
Publicado: (2023)

Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial
por: Piazza, Gregory, et al.
Publicado: (2023)

Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis
por: Miao, Benjamin, et al.
Publicado: (2019)

Body site microbiota of Magellanic and king penguins inhabiting the Strait of Magellan follow species-specific patterns
por: Ochoa-Sánchez, Manuel, et al.
Publicado: (2023)

Extended Thromboprophylaxis in Patients with COVID-19
por: Zhao, Wei, et al.
Publicado: (2021)

Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions
por: Kreutz, Reinhold, et al.
Publicado: (2016)

Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis
por: Lindquist, Desirae E., et al.
Publicado: (2018)

Lateralization (handedness) in Magellanic penguins
por: Stor, Thaís, et al.
Publicado: (2019)

Observations of a Magellanic Corona
por: Krishnarao, Dhanesh, et al.
Publicado: (2022)

Current knowledge of the Southern Hemisphere marine microbiome in eukaryotic hosts and the Strait of Magellan surface microbiome project
por: Ochoa-Sánchez, Manuel, et al.
Publicado: (2023)

The population of supernova remnants in the Magellanic Clouds
por: Dennefeld, M
Publicado: (1978)

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
por: Prins, Martin H, et al.
Publicado: (2013)

Laboratory assessment of rivaroxaban: a review
por: Samama, Meyer Michel, et al.
Publicado: (2013)

Effects of thromboprophylaxis on mesenchymal stromal cells during osteogenic differentiation: an in-vitro study comparing enoxaparin with rivaroxaban
por: Pilge, Hakan, et al.
Publicado: (2016)

Comparison of efficiency and safety of rivaroxaban, apixaban and enoxaparin for thromboprophylaxis after arthroplastic surgery: a meta-analysis
por: Yu, Zhi, et al.
Publicado: (2018)

Clinical Outcomes and Costs of Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Inpatients: A Cross-Sectional Study
por: Lenci Marques, Gustavo, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of Rivaroxaban and Enoxaparin as Thromboprophylaxis Agents for Orthopedic Surgery—Systematic Review and Meta-Analysis
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery: A Randomized Clinical Trial
por: Kröll, Dino, et al.
Publicado: (2023)

Improved Campephiline detection: An experiment conducted with the Magellanic Woodpecker
por: Wynia, Amy L., et al.
Publicado: (2019)

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022)

NGC1818 unveils the origin of the extended main-sequence turn-off in young Magellanic Clouds clusters
por: Cordoni, Giacomo, et al.
Publicado: (2022)

Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?
por: Iba, Toshiaki, et al.
Publicado: (2021)

Conference on New Aspects of Magellanic Cloud Research
por: Klare, G
Publicado: (1992)

Workshop on the Magellanic Clouds and other Dwarf Galaxies
por: Braun, J M, et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_0dgfroistm4pphn9tossun86h9